Statistics

Total Visits

Views
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials.52

Select a period of time:

Number of views in the range

Views
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials.18

Views

Views
June 20250
July 202514
August 20251
September 20250
October 20252
November 20251
December 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Brazil8
Venezuela2
Angola1
Argentina1
Colombia1
Egypt1
Spain1
France1
Peru1
United States1
 

Top cities views

Views
São Paulo2
Bauru1
Bogotá1
Caracas1
Dallas1
Giza1
Itapevi1
Lima1
Luanda1
Madrid1